Nantahala Capital Partners Limited Partnership's Schedule 13G Filing for Abeona Therapeutics Inc.

Nantahala Capital Partners Limited Partnership filed a Schedule 13G with the SEC on October 6, 2025, disclosing its beneficial ownership of shares in Abeona Therapeutics Inc. As of September 29, 2025, Nantahala may be deemed to be the beneficial owner of 2,618,462 shares, representing 5.09% of the total outstanding shares of Abeona Therapeutics Inc. This includes 179,832 shares that may be acquired within sixty days through the exercise of securities. The filing certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The filing was signed by Taki Vasilakis, Wilmot B. Harkey, and Daniel Mack, all of Nantahala Capital Management, LLC.